Key statistics
As of last trade, WAVE Life Sciences Ltd (WVE:NMQ) traded at 12.80, 142.42% above the 52 week low of 5.28 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 13.16 |
|---|---|
| High | 13.16 |
| Low | 12.61 |
| Bid | 12.78 |
| Offer | 12.81 |
| Previous close | 12.80 |
| Average volume | 2.57m |
|---|---|
| Shares outstanding | 182.74m |
| Free float | 157.64m |
| P/E (TTM) | -- |
| Market cap | 2.34bn USD |
| EPS (TTM) | -0.7363 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 18:19 GMT.
More ▼
- Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
- Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
- Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
- Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
- Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
- Wave Life Sciences to Present at Upcoming Investor Conferences
- Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
More ▼
